BMS reports phase 3 successes in IPF drug and neuroendocrine tumor radiotherapy
Bristol Myers Squibb announced that two of its phase 3 trials have met primary endpoints, marking important milestones as the company seeks growth beyond its patent expirations.
The Aloft-IPF study evaluated the LPA1 antagonist admilparant in adults with idiopathic pulmonary fibrosis. The 60 mg dose showed a statistically significant improvement in forced vital capacity at week 52, while the higher 120 mg dose did not reach significance.
The Action-1 trial tested the radiopharmaceutical RYZ101 in patients with somatostatin-receptor positive gastroenteropancreatic neuroendocrine tumors. The study also achieved its primary endpoint, supporting the therapy’s potential.
BMS said the combined data support admilparant as a first-in-class option and plans to discuss regulatory filing. Analysts have previously valued the IPF program at over $5 billion, highlighting its strategic importance.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that